Literature DB >> 20407460

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

J A Wagner1, M Prince, E C Wright, M M Ennis, J Kochan, D J R Nunez, B Schneider, M-D Wang, Y Chen, S Ghosh, B J Musser, M T Vassileva.   

Abstract

Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public-private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator-activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross-company precompetitive collaboration is a feasible robust approach to biomarker qualification.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20407460     DOI： 10.1038/clpt.2009.227

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  9 in total

1.  Pharma embraces open source models.

Authors:  Stephen Strauss
Journal:  Nat Biotechnol       Date:  2010-07       Impact factor: 54.908

2.  Teaming up for biomarker future. Many problems still hinder the use of biomarkers in clinical practice, but new public-private partnerships could improve the situation.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2011-06       Impact factor: 8.807

3.  Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  J Pharm Bioallied Sci       Date:  2010-10

4.  Optimization of current and future therapy for autoimmune diseases.

Authors:  Lawrence Steinman; Joan T Merrill; Iain B McInnes; Mark Peakman
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

5.  Crowdsourced Asparagus Urinary Odor Population Kinetics.

Authors:  Anuradha Ramamoorthy; Brian M Sadler; J G Coen van Hasselt; Jeroen Elassaiss-Schaap; Sreeneeranj Kasichayanula; Alena Y Edwards; Piet H van der Graaf; Lei Zhang; John A Wagner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-12-14

Review 6.  Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients.

Authors:  Magdalini Papadaki
Journal:  Front Med (Lausanne)       Date:  2017-05-29

7.  The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction.

Authors:  Joseph P Menetski; Steven C Hoffmann; Stephanie S Cush; Tania Nayak Kamphaus; Christopher P Austin; Paul L Herrling; John A Wagner
Journal:  Clin Pharmacol Ther       Date:  2019-04       Impact factor: 6.875

8.  Integration of patient-reported outcomes in multiregional confirmatory clinical trials.

Authors:  Ari Gnanasakthy; Carla DeMuro; Caroline Boulton
Journal:  Contemp Clin Trials       Date:  2013-02-13       Impact factor: 2.226

Review 9.  Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.

Authors:  Mirjana Babić; Dubravka Svob Štrac; Dorotea Mück-Šeler; Nela Pivac; Gabrijela Stanić; Patrick R Hof; Goran Simić
Journal:  Croat Med J       Date:  2014-08-28       Impact factor: 1.351
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.